Carboxy-terminal provasopressin may predict prognosis in nursing home acquired pneumonia

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 226-229

  Kim, Sang Hwan ^a   Chung, Jae Ho ^a   Lee, Jong Chan ^b   Park, Yo Han ^b   Joe, Jun Hyeon ^b   Hwang, Hee Jin ^a  

^a Catholic Kwandong University   (South Korea)

^b Yonsei Sarang Hospital   (South Korea)

Author keywords

Aged; Copeptin; Mortality; Nursing home acquired pneumonia; Pro atrial natriuretic peptide; Procalcitonin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; COPEPTIN; NITROGEN; PROATRIAL NATRIURETIC FACTOR; PROCALCITONIN; UNCLASSIFIED DRUG; UREA;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CARBOXY TERMINAL SEQUENCE; CLINICAL EVALUATION; CONFUSION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING HOME ACQUIRED PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CALCITONIN; CROSS INFECTION; FEMALE; GLYCOPEPTIDES; HOMES FOR THE AGED; HUMANS; MALE; NURSING HOMES; PNEUMONIA, BACTERIAL; PROGNOSIS; PROTEIN PRECURSORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84876448062     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.022     Document Type: Article

References (44)

1. Muder R.R., Brennen C., Swenson D.L., Wagener M. Pneumonia in a long-term care facility. A prospective study of outcome. Arch Intern Med 1996, 156:2365-2370.
2. Marrie T.J., Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997, 45:50-55.
3. Mylotte J.M., Goodnough S., Gould M. Pneumonia versus aspiration pneumonitis in nursing home residents: prospective application of a clinical algorithm. J Am Geriatr Soc 2005, 53:755-761.
4. Marrie T.J. Pneumonia in the long-term-care facility. Infect Control Hosp Epidemiol 2002 Mar, 23(3):159-164.
5. Masia M., Gutierrez F., Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005, 128:2223-2229.
6. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
7. Hedlund J., Hansson L.O. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000, 28:68-73.
8. Jochberger S., Morgenthaler N.G., Mayr V.D., et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006, 91:4281-4286.
9. Morgenthaler N.G., Struck J., Christ-Crain M., Bergmann A., Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005, 9:R37-R45.
10. Krur̈ger S., Papassotiriou J., Marre R., et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia. Intensive Care Med 2007, 33:2069-2078.
11. Mur̈ller B., Suess E., Schuetz P., et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infection. J Intern Med 2006, 260:568-576.
12. El-Solh A.A. Nursing home acquired pneumonia: approach to management. Curr Opin Infect Dis 2011, 24:148-151.
13. Niederman M.S., Feldman C., Richards G.A. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006, 27:9-11.
14. McGeer A., Campbell B., Emori T.G., et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991, 19:1-7.
15. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
16. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
17. Almirall J., Bolibar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
18. Smith R.P., Lipworth B.J., Cree I.A., Spiers E.M., Winter J.H. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995, 108:1288-1291.
19. Garcia Vazquez E., Martinez J.A., Mensa J., et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003, 21:702-705.
20. Macfarlane J.T., Boldy D. 2004 update of BTS pneumonia guidelines: what's new?. Thorax 2004, 59:364-366.
21. Whicher J., Bienvenu J., Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001, 38:483-493.
22. Nijsten M.W., Olinga P., The T.H., et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000, 28:458-461.
23. Oberhoffer M., Stonans I., Russwurm S., et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999, 134:49-55.
24. Muller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129.
25. Kruger S., Ewig S., Papassotiriou J., et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65.
26. Schuetz P., Albrich W., Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011, 9:107.
27. Aalto H., Takala A., Kautiainen H., et al. Laboratory markers of systemic inflammation as predictors of bloodstream infection in acutely ill patients admitted to hospital in medical emergency. Eur J Clin Microbiol Infect Dis 2004, 23:699-704.
28. Liaudat S., Dayer E., Praz G., et al. Usefulness of procalcitonin serum level for the diagnosis of bacteremia. Eur J Clin Microbiol Infect Dis 2001, 20:524-527.
29. Suprin E., Camus C., Gacouin A., et al. Procalcitonin: a valuable indicator of infection in a medical ICU?. Intensive Care Med 2000, 26:1232-1238.
30. Giamarellos-Bourboulis E.J., Mega A., Greeka A., et al. Procalcitonin a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. Intensive Care Med 2002, 28:1351-1356.
31. Ugarte H., Silva E., Mercan D., et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999, 27:498-504.
32. Nishikimi T., Maeda N., Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006, 69:318-328.
33. Vollmar A.M. The role of atrial natriuretic peptide in the immune system. Peptides 2005, 26:1086-1094.
34. Wiedermann C.J., Niedermuhlbichler M., Braunsteiner H. Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest 1992, 89:1580-1586.
35. Banach M., Goch A., Misztal M., et al. Relation between postoperative mortality and atrial fibrillation before surgical revascularization-3-year follow-up. Thorac Cardiovasc Surg 2008, 56:20-23.
36. Piechota M., Barylski M., Hannam S., Mikhailidis D.P., Rysz J., Banach M. Natriuretic peptides in septic patients. Curr Med Chem 2009, 16:4020-4031.
37. Lipinska-Gediga M., Mierzchala M., Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection 2012, 40:303-309.
38. Katan M., Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010, 140:w13101.
39. Nickel C.H., Bingisser R., Morgenthaler N.G. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012, 10:7.
40. Katan M., Muller B., Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008, 12:117.
41. Man S.Y., Graham C.A., Chan S.S., et al. Disease severity prediction for nursing home acquired pneumonia in the emergency department. Emerg Med J 2011, 28:1046-1050.
42. El-Solh A.A., Alhajhusain A., Abou Jaoude P., et al. Validity of severity scores in hospitalized patients with nursing home acquired pneumonia. Chest 2010, 138:1371-1376.
43. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119.
44. Jochberger S., Morgenthaler N.G., Mayr V.D., et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006, 91:4381-4386.